Navigating Polycythemia Vera Treatment Options
by David Wallace 2024 Patients Are Asking, Episode 2 In this MPN expert interview, Dr. Gaby Hobbs shares her expertise on the various treatment options for Polycythemia Vera (PV). She explains first-line therapies, including phlebotomy, hydroxyurea, interferon (Besremi), Jakafi and highlights the importance of individualized treatment based on patient-specific factors. Watch the full interview to […]
Myelofibrosis Treatment: Optimizing JAK Inhibitor Strategies in 2024
by David Wallace 2024 Patients Are Asking, Episode 1 In our ongoing effort to provide the latest insights and resources for the MPN community, we’re excited to share an informative video on tailoring JAK inhibitor treatment strategies for myelofibrosis. Our interview with MPN expert, Dr. Lucia Masarova covers important aspects of JAK inhibitors, their role […]
MPN Research 2024: Emerging Trends
by David Wallace ASH 2023 Highlights: Patients Are Asking, Episode 3 Discover the latest MPN research from the ASH 2023 conference with MPN expert, Dr. Lucia Masarova. We cover the latest clinical trials, breakthrough treatments, and innovative approaches to MPN blood cancers. Learn about combination treatments for myelofibrosis and updates on clinical trials for polycythemia […]
Optimizing MPN Patient Outcomes: The Holistic Approach
Optimizing MPN Patient Outcomes: The Holistic Approach by David Wallace Join us as we sit down with renowned MPN expert, Dr. Angela Fleischman, for an enlightening conversation about living optimally with Myeloproliferative Neoplasms. Dive deep into actionable strategies for managing myelofibrosis and discover tips to enhance your journey with MPNs. Your host, David Wallace, founder […]
MPN Specialist Interview 2023
by David Wallace Patients Are Asking – Episode 1 In this interview with MPN specialist, Dr. Ghaith Abu-Zeinah, we learn what the term “disease modification” means. We discuss promising late-stage clinical trials and the importance of tracking your symptoms to discuss with your physician. David Wallace, PV Reporter, is your host and patient advocate. […]
Effectiveness and Safety of Ruxolitinib in Newly Diagnosed PV Patients
Abstract Patients (pts) with polycythemia vera (PV) suffer from pruritus, night sweats, and other symptoms, as well as from thromboembolic complications and progression to post-PV myelofibrosis. Ruxolitinib (RUX) is approved for second-line therapy in high-risk PV pts with hydroxyurea intolerance or resistance. The RuxoBEAT trial (NCT02577926, registered on October 1, 2015, at clinicaltrials.gov) is a […]
New Developments in MPN Research 2023
by David Wallace Patients are Asking – MPN Specialist Dr. Srdan Verstovsek – Episode 3 of 3 Interview with MPN expert, Dr. Srdan Verstovsek from ASH 2022. Learn about an exciting new anti-mutant calreticulin (CALR) targeted monoclonal antibody that may lead to a molecular response in MF and ET. What were some of the highlights […]
MPN Clinical Trial update with Dr. Angela Fleischman
by David Wallace Patients are Asking – Episode 2 of 3 In this interview with MPN expert, Dr. Angela Fleischman, we discuss the latest treatments for myelofibrosis (MF) and when a clinical trial should be considered. Research has linked MPNs to a pre-disposition to auto-immune disorders such as Lupus, Crohn’s disease and Psoriasis just to […]
What Treatments for MPN in late stage clinical trials look most promising in 2022?
by David Wallace Patients are Asking – MPN Specialist Dr. Michael Grunwald, from Levine Cancer Institute discusses new medications for myeloproliferative neoplasms Episode 1 of 3 Dr. Grunwald also provides insight into how to get a referral to see an MPN expert. Featuring: Dr. Michael Grunwald Thank you to our Sponsors
JAK2 in Myeloproliferative Neoplasms
Abstract: The discovery of the activating V617F mutation in Janus kinase 2 (JAK2) has been decisive for the understanding of myeloproliferative neoplasms (MPN). Activated JAK2 signaling by JAK2, CALR, and MPL mutations has become a focus for the development of targeted therapies for patients with MPN. JAK2 inhibitors now represent a standard of clinical care for certain forms of MPN […]
New FDA Approved Treatment for Polycythemia Vera
New FDA Approved Treatment for Polycythemia Vera Patients are Asking – MPN ExpertDr. Abu-Zeinah discussesRopeginterferon, FDA ApprovedTreatment for Polycythemia Vera Episode 3 of 3 Ropeginterferon / BESREMi was recently approved by the FDA to treat Polycythemia Vera. Patients are asking: Should I switch from Pegasys to the new FDA approved Ropeginterferon? How might Ropeginterferon change […]
The Health Benefits of Social Connections for Myeloproliferative Neoplasm Patients
by Lou Ann Donovan We all enjoy getting together with friends and attending family gatherings from time to time. Such occasions give us an opportunity to catch up, share ideas, and even lend support to each other. Social connections like these also influence our health and longevity the same as our diet, sleep, and exercise. […]
